Details of the Drug

General Information of Drug (ID: DMGDKXN)

Drug Name
Sitagliptin
Synonyms
486460-32-6; Januvia; Xelevia; Sitagliptan; MK-0431; UNII-QFP0P1DV7Z; Tesavel; QFP0P1DV7Z; (3R)-3-AMINO-1-[3-(TRIFLUOROMETHYL)-5H,6H,7H,8H-[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7-YL]-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE; (2R)-4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE; CHEBI:40237; (R)-3-AMINO-1-(3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL)-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE; Janumet; Sitagliptin phosphate; Januvia (TN); Sitagliptin (PropINN); Januvia (merck & Co); (3R)-3-Amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; (3R)-3-amino-1-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; (3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; Sitagliptin/atovastatin
Indication
Disease Entry ICD 11 Status REF
Cystic fibrosis CA25 Approved [1]
Non-insulin dependent diabetes 5A11 Approved [1]
Renal hypoplasia N.A. Approved [1]
Type-2 diabetes 5A11 Approved [2]
Peripheral arterial disease BD4Z Phase 1/2 [3]
Therapeutic Class
Hypoglycemic Agents
Affected Organisms
Humans and other mammals
ATC Code
A10BH01: Sitagliptin
A10BH: Dipeptidyl peptidase 4 (DPP-4) inhibitors
A10B: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10: DRUGS USED IN DIABETES
A: ALIMENTARY TRACT AND METABOLISM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 407.31
Logarithm of the Partition Coefficient (xlogp) 0.7
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 10
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [4]
Bioavailability
87% of drug becomes completely available to its intended biological destination(s) [5]
Clearance
The clearance of drug is 350 mL/min [6]
Elimination
87% of the dose is eliminated in the urine and 13% in the feces [7]
Half-life
The concentration or amount of drug in body reduced by one-half in 12.4 hours [7]
Metabolism
The drug is metabolized via the cytochrome p450(CYP)3A4 and to a lesser extent by CYP2C8 [8]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.35072 micromolar/kg/day [9]
Unbound Fraction
The unbound fraction of drug in plasma is 0.62% [10]
Vd
The volume of distribution (Vd) of drug is 198 L []
Chemical Identifiers
Formula
C16H15F6N5O
IUPAC Name
(3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
Canonical SMILES
C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N
InChI
InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1
InChIKey
MFFMDFFZMYYVKS-SECBINFHSA-N
Cross-matching ID
PubChem CID
4369359
ChEBI ID
CHEBI:40237
CAS Number
486460-32-6
UNII
QFP0P1DV7Z
DrugBank ID
DB01261
TTD ID
D0U2JP
VARIDT ID
DR00254
INTEDE ID
DR1490
ACDINA ID
D00628
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dipeptidyl peptidase 4 (DPP-4) TTDIGC1 DPP4_HUMAN Inhibitor [11]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [12]
Organic anion transporter 3 (SLC22A8) DTVP67E S22A8_HUMAN Substrate [13]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [14]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [15]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [15]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Cystic fibrosis
ICD Disease Classification CA25
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dipeptidyl peptidase 4 (DPP-4) DTT DPP4 9.54E-01 -0.27 -1.85
Organic anion transporter 3 (SLC22A8) DTP OAT3 6.49E-01 3.37E-03 6.66E-02
P-glycoprotein 1 (ABCB1) DTP P-GP 2.30E-01 3.06E-01 7.43E-01
Organic cation transporter 1 (SLC22A1) DTP SLC22A1 1.46E-01 2.34E-01 7.18E-01
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 4.79E-01 -1.88E-02 -1.73E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 2.76E-01 -4.64E-01 -9.16E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MHH-NB-11 CTRP2 7.5514 9.3234 5.4255 0.7711
Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuCC-T1 CTRP2 6.9706 9.0191 5.2398 1.9569
HuH-28 CTRP2 7.1671 8.5915 5.5401 0.7037
SNU-1079 CTRP2 7.2685 9.2056 4.3986 0.4857
SNU-478 CTRP2 7.7713 9.9914 5.2565 1.1201
SNU-308 CTRP2 8.0665 9.3929 5.6155 0.1387
SNU-1196 CTRP2 8.505 9.7904 5.6346 0.0577
⏷ Show the Full List of 6 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MHH-ES-1 CTRP2 7.8487 11.7625 4.5125 3.6753
SW1353 CTRP2 11.6569 20.5225 2.7745 5.8115
Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KPL-1 CTRP2 6.5775 7.8705 5.5282 1.3309
CAL-148 CTRP2 7.5776 9.137 5.5127 0.516
CAL-51 CTRP2 7.6979 9.5169 5.4162 0.7018
HDQ-P1 CTRP2 7.803 9.4852 5.4762 0.4886
MCF-7 CTRP2 7.9144 12.5017 4.2094 4.7581
HMC-1-8 CTRP2 7.9703 9.1079 5.6793 0.0826
HCC1937 CTRP2 8.2061 10.0756 5.4218 0.43
JIMT-1 CTRP2 8.2149 9.7853 5.532 0.2232
HCC1395 CTRP2 8.4304 10.4896 5.3588 0.4713
CAMA-1 CTRP2 9.1388 22.6433 0.1612 17.2603
⏷ Show the Full List of 10 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-38 CTRP2 7.6347 8.5408 5.7542 0.0575
Cancer Drug Sensitivity Data Curated from 16 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NMC-G1 CTRP2 6.1077 7.1862 5.5254 2.0625
SNU-466 CTRP2 6.6282 9.0934 4.9748 3.4868
U-87MG ATCC CTRP2 6.8738 9.1069 5.1369 2.4791
SF295 CTRP2 6.9376 9.6764 4.908 3.3027
SNU-201 CTRP2 7.2303 8.6112 4.5992 0.1363
SNU-1105 CTRP2 7.2434 9.8052 5.0444 2.3746
SNU-489 CTRP2 7.2962 9.1859 5.3534 1.2014
LN-18 CTRP2 7.5018 8.6509 5.666 0.2083
CAS-1 CTRP2 7.6365 9.0071 5.5882 0.3118
SNU-626 CTRP2 7.8934 9.2292 5.6086 0.189
SNU-738 CTRP2 7.9319 9.2179 5.6272 0.152
SF126 CTRP2 8.0337 9.2913 5.6389 0.1162
GB-1 CTRP2 8.0448 9.7085 5.4931 0.347
LN-229 CTRP2 8.414 12.1842 4.6519 2.5626
ONS-76 CTRP2 8.4447 10.0896 5.5105 0.1981
Daoy CTRP2 8.6251 12.2168 4.7509 2.0417
⏷ Show the Full List of 16 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HEC-265 CTRP2 6.6475 8.155 5.4394 1.5872
HEC-251 CTRP2 7.3654 9.3131 5.3354 1.1999
HEC-108 CTRP2 7.4847 8.9872 5.53 0.5232
RL95-2 CTRP2 7.6194 11.8996 4.3024 4.7794
HEC-1-B CTRP2 7.6716 13.1251 3.7513 6.8937
HEC-59 CTRP2 7.6799 9.7191 5.3247 0.9795
KLE CTRP2 7.6814 10.8929 4.8104 2.7496
HEC-6 CTRP2 7.9426 9.6992 5.4539 0.474
JHUEM-2 CTRP2 8.0609 9.7661 5.4781 0.3711
Ishikawa (Heraklio) 02 ER- CTRP2 7.8532 9.0017 5.6739 0.1078
⏷ Show the Full List of 10 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 34 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JVM-3 CTRP2 5.6209 10.1619 2.9488 8.2976
ALL-SIL CTRP2 6.2287 7.6101 5.4093 2.3341
NCI-H929 CTRP2 6.9234 9.7856 4.846 3.5723
KM-H2 CTRP2 6.9877 9.5686 4.9928 2.8966
WSU-DLCL2 CTRP2 7.0041 9.1177 5.2149 2.0115
HT CTRP2 7.0661 9.9047 4.885 3.2182
MV4-11 CTRP2 7.1148 8.8813 5.3874 1.2552
RPMI-8402 CTRP2 7.3445 8.9338 5.4854 0.739
HDLM-2 CTRP2 7.362 9.6488 5.1857 1.7224
Ki-JK CTRP2 7.3964 9.0246 5.4733 0.7382
LAMA-84 CTRP2 7.4279 9.4762 5.2981 1.269
KMS-26 CTRP2 7.501 8.3983 5.7556 0.0758
NALM-6 CTRP2 7.5062 12.4778 3.9495 6.3418
KE-97 CTRP2 7.5085 10.9466 4.6795 3.4499
EHEB CTRP2 7.5965 9.491 5.3783 0.8786
KMS-27 CTRP2 7.6453 9.1273 5.5462 0.4002
SU-DHL-1 CTRP2 7.6565 8.5566 5.7565 0.0528
KE-37 CTRP2 7.6654 8.8213 5.6678 0.1573
DEL CTRP2 7.7017 8.6918 5.7264 0.0749
Jurkat CTRP2 7.7246 9.4328 5.462 0.5646
P31/FUJ CTRP2 7.7333 9.0358 5.6166 0.2223
KCL-22 CTRP2 7.7558 9.9189 5.2791 1.062
P12-Ichikawa CTRP2 7.8855 9.1397 5.6375 0.1482
Ku812 CTRP2 7.915 10.0865 5.2876 0.924
EM-2 CTRP2 7.9944 9.4385 5.5721 0.2197
MOLM-13 CTRP2 8.0051 9.6911 5.4833 0.3824
CML-T1 CTRP2 8.026 9.5964 5.527 0.2887
HEL CTRP2 8.1128 9.2471 5.6819 0.062
PF-382 CTRP2 8.1178 9.9172 5.4448 0.4174
JURL-MK1 CTRP2 8.2303 9.7883 5.5368 0.2117
KMS-21-BM CTRP2 8.3105 10.1526 5.4356 0.3623
Peer CTRP2 8.3634 9.8324 5.5706 0.1367
NCO2 CTRP2 8.3771 10.2041 5.4433 0.3253
KMM-1 CTRP2 8.7055 10.6826 5.3976 0.3036
⏷ Show the Full List of 34 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TUHR4TKB CTRP2 7.0742 8.5244 5.521 0.8385
BFTC-909 CTRP2 7.7357 9.0614 5.6082 0.2365
OS-RC-2 CTRP2 7.8219 9.8062 5.3575 0.7867
SNU-1272 CTRP2 8.1288 9.4583 5.6154 0.1266
KMRC-20 CTRP2 8.3318 9.8052 5.5686 0.145
Cancer Drug Sensitivity Data Curated from 13 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-175 CTRP2 6.0392 18.2396 -0.0576 23.2579
SNU-81 CTRP2 6.7597 11.3112 3.9808 7.3809
HT-29 CTRP2 7.3198 8.4742 5.6575 0.2961
DLD-1 CTRP2 7.543 8.4879 5.7397 0.0866
LS411N CTRP2 7.5522 8.8631 5.6075 0.3054
HT115 CTRP2 7.6267 9.3149 5.4643 0.6144
HCT 116 CTRP2 7.7168 9.2196 5.5413 0.3789
COLO205 CTRP2 7.9516 9.0576 5.6898 0.075
SW48 CTRP2 8.1353 9.7486 5.5145 0.2757
OUMS-23 CTRP2 8.1886 9.1542 5.7381 0.0222
LS513 CTRP2 8.3271 9.6068 5.635 0.0763
LS180 CTRP2 8.3286 10.0174 5.4922 0.2557
SK-CO-1 CTRP2 8.3293 9.8045 5.568 0.1464
⏷ Show the Full List of 13 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 4 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Hep 3B2.1-7 CTRP2 7.1873 10.9888 4.4477 4.799
SNU-878 CTRP2 7.9193 9.4067 5.5543 0.2742
Li-7 CTRP2 8.5999 11.0761 5.2063 0.7399
SNU-182 CTRP2 9.5385 22.4316 0.5484 15.5311
Cancer Drug Sensitivity Data Curated from 42 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H2291 CTRP2 6.798 10.3471 4.4842 5.2383
HCC827 CTRP2 7.1119 9.8521 4.9397 2.9418
NCI-H1734 CTRP2 7.244 9.5378 5.1672 1.9146
RERF-LC-Ad1 CTRP2 7.2869 17.2243 1.4532 16.2122
MOR/CPR CTRP2 7.2938 8.1731 5.7583 0.115
BEN CTRP2 7.3161 8.2651 5.7338 0.1476
LCLC-103H CTRP2 7.3511 8.7722 5.5546 0.5366
SBC-5 CTRP2 7.4699 8.5777 5.6802 0.1931
NCI-H526 CTRP2 7.4767 8.8988 5.5613 0.4475
NCI-H2106 CTRP2 7.5409 10.3995 4.9514 2.3838
Lu-99 CTRP2 7.5417 9.5306 5.3343 1.0554
HCC44 CTRP2 7.5772 14.9562 2.7925 10.818
NCI-H196 CTRP2 7.752 9.2634 5.5395 0.3676
NCI-H2009 CTRP2 7.7653 9.3843 4.5245 0.1294
NCI-H460 CTRP2 7.8713 9.011 5.6773 0.1006
HCC1588 CTRP2 7.8789 10.0985 5.2652 1.0145
NCI-H727 CTRP2 7.8943 9.5937 5.4737 0.4509
A-549 CTRP2 7.9207 9.6777 4.4793 0.1543
NCI-H69 CTRP2 7.9406 9.6628 5.4669 0.4453
HCC95 CTRP2 7.9509 12.5847 4.1938 4.7723
HCC78 CTRP2 7.9718 9.7652 5.441 0.49
NCI-H2030 CTRP2 7.9901 10.9895 4.9432 1.9594
SHP-77 CTRP2 7.9902 9.2483 5.638 0.1254
RERF-LC-A1 CTRP2 8.0277 10.0925 5.3377 0.7162
HCC15 CTRP2 8.0484 10.0929 5.347 0.6806
NCI-H1155 CTRP2 8.0501 9.5296 5.5608 0.2225
CAL-12T CTRP2 8.0763 9.7695 5.4831 0.3551
NCI-H650 CTRP2 8.1688 9.8045 5.5073 0.2779
NCI-H1838 CTRP2 8.2007 9.778 5.5292 0.2315
NCI-H358 CTRP2 8.2615 10.0969 5.4365 0.3783
NCI-H211 CTRP2 8.2743 10.668 5.2211 0.8815
HCC366 CTRP2 8.3442 10.0648 5.4811 0.2696
NCI-H292 CTRP2 8.363 9.8834 5.5527 0.1589
NCI-H1581 CTRP2 8.4861 10.1548 5.5029 0.1992
NCI-H1299 CTRP2 8.515 10.8887 5.2421 0.6963
HCC1833 CTRP2 8.7026 15.2713 3.4135 6.8032
HARA [Human squamous cell lung carcinoma] CTRP2 8.7032 10.5671 5.4381 0.2409
NCI-H2405 CTRP2 9.3964 11.4307 5.3903 0.1629
HCC2108 CTRP2 10.0342 18.3368 2.8192 7.3511
HCC2279 CTRP2 10.3205 19.8886 2.2784 8.8859
HCC1171 CTRP2 10.5427 20.4018 2.1783 8.9601
Calu-3 CTRP2 12.839 32.9004 -2.2303 18.3041
⏷ Show the Full List of 42 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE-9 CTRP2 7.6349 9.1832 5.52 0.4673
TE-10 CTRP2 8.1633 10.9005 5.0721 1.3913
KYSE-140 CTRP2 8.2108 14.4941 3.46 7.2774
COLO 680N CTRP2 8.3135 9.839 5.5501 0.1728
KYSE-180 CTRP2 8.7356 15.4485 3.3514 6.9954
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
OVTOKO CTRP2 7.4975 9.5793 5.2906 1.2331
SNU-119 CTRP2 7.6579 12.3819 4.0985 5.533
JHOC-5 CTRP2 7.8042 11.698 4.5149 3.7196
SNU-8 CTRP2 7.8706 8.7632 5.7605 0.03
ONCO-DG-1 CTRP2 8.2845 9.601 5.622 0.0938
Kuramochi CTRP2 8.6838 11.1309 5.2215 0.6631
OVSAHO CTRP2 12.0126 23.3566 1.7112 8.826
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-213 CTRP2 7.4252 10.3677 4.8964 2.7211
KP-4 CTRP2 7.7735 9.207 5.5696 0.2966
SUIT-2 CTRP2 7.9439 9.3879 5.5709 0.2367
KP-3 CTRP2 7.978 10.5093 5.1431 1.3136
CFPAC-1 CTRP2 8.1703 9.4895 5.6196 0.1143
BxPC-3 CTRP2 8.1787 9.8997 5.4762 0.3313
⏷ Show the Full List of 6 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H28 CTRP2 8.0565 9.6544 5.5178 0.2954
ACC-MESO-1 CTRP2 8.1731 9.3675 5.6622 0.0714
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-15 CTRP2 7.4991 8.9492 5.5515 0.4602
Cancer Drug Sensitivity Data Curated from 4 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-375 CTRP2 7.472 8.919 4.5797 0.1164
SK-MEL-1 CTRP2 7.628 9.559 5.3656 0.894
RPMI-7951 CTRP2 7.802 9.1177 5.6136 0.2065
Mel Ho CTRP2 7.9968 9.5451 5.5342 0.2851
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Rh41 CTRP2 7.4221 9.1914 5.4166 0.8911
Cancer Drug Sensitivity Data Curated from 15 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
GSU CTRP2 6.7975 7.5304 5.7962 0.221
NCI-N87 CTRP2 6.8011 9.9207 4.6949 4.3678
MKN45 CTRP2 7.133 8.1632 5.6969 0.2923
23132/87 CTRP2 7.2989 8.6773 4.601 0.1215
SNU-668 CTRP2 7.3798 11.7302 4.2227 5.4276
GSS CTRP2 7.4877 8.8381 5.5897 0.3735
AGS CTRP2 7.7366 9.0345 5.6183 0.2182
NUGC-4 CTRP2 7.7387 12.1953 4.2404 4.8646
MKN1 CTRP2 7.7552 9.1093 5.5983 0.2481
SNU-620 CTRP2 7.767 8.8941 5.68 0.1169
SNU-5 CTRP2 7.7941 9.193 5.583 0.2633
ECC12 CTRP2 7.8435 8.9054 5.7036 0.0769
SNU-719 CTRP2 8.3591 10.6255 5.2761 0.6926
KE-39 CTRP2 9.3264 12.2329 5.0733 0.708
SNU-1077 CTRP2 8.4298 10.2462 5.4486 0.2992
⏷ Show the Full List of 15 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
8305C CTRP2 6.8424 8.644 4.4315 0.6192
CGTH-W-1 CTRP2 7.6171 9.3061 5.4634 0.6225
BHT-101 CTRP2 7.6981 9.1295 5.5676 0.33
TT CTRP2 7.8047 13.3282 3.7445 6.7298
CAL-62 CTRP2 7.988 9.3804 5.5906 0.1921
B-CPAP CTRP2 8.0015 9.5663 5.5283 0.2946
8505C CTRP2 8.246 11.0353 5.0571 1.3749
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Detroit 562 CTRP2 6.9398 11.1339 4.2018 6.1755
YD-10B CTRP2 7.465 9.1672 5.4479 0.7652
HSC-3 CTRP2 7.5546 9.2334 5.4636 0.6604
SNU-1214 CTRP2 7.5659 10.3258 4.9994 2.1815
SNU-1076 CTRP2 7.5772 8.9021 4.6219 0.064
SNU-899 CTRP2 7.578 9.3426 5.4304 0.739
SNU-46 CTRP2 7.7461 11.1607 4.7269 2.9875
SNU-1066 CTRP2 8.0866 9.786 5.4812 0.355
BHY CTRP2 8.295 10.2332 5.3992 0.4412
SNU-1041 CTRP2 8.8113 10.5053 5.4994 0.14
⏷ Show the Full List of 10 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
639V CTRP2 7.3535 8.3223 5.7276 0.1471
JMSU-1 CTRP2 7.4183 8.941 5.5179 0.5958
KU-19-19 CTRP2 7.4754 8.8407 5.5834 0.3944
253J CTRP2 7.6244 8.9043 5.6216 0.2494
BFTC-905 CTRP2 7.6454 8.7549 5.6839 0.1384
VM-CUB-1 CTRP2 7.8689 9.6593 5.4373 0.5497
CAL-29 CTRP2 7.888 9.3853 5.5497 0.2937
253J-BV CTRP2 7.985 9.3315 5.6068 0.1686
TCCSUP CTRP2 8.0085 10.0618 5.3412 0.718
5637 CTRP2 8.0471 13.1623 3.9841 5.4613
⏷ Show the Full List of 10 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Sitagliptin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Arn-509 DMT81LZ Moderate Increased metabolism of Sitagliptin caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [16]
Erdafitinib DMI782S Moderate Decreased clearance of Sitagliptin due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [17]
Tucatinib DMBESUA Moderate Decreased clearance of Sitagliptin due to the transporter inhibition by Tucatinib. Breast cancer [2C60-2C6Y] [18]
BMS-201038 DMQTAGO Moderate Decreased clearance of Sitagliptin due to the transporter inhibition by BMS-201038. Hyper-lipoproteinaemia [5C80] [19]
Ibrutinib DMHZCPO Moderate Decreased clearance of Sitagliptin due to the transporter inhibition by Ibrutinib. Mature B-cell lymphoma [2A85] [16]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Sitagliptin caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [20]
Lasmiditan DMXLVDT Moderate Decreased clearance of Sitagliptin due to the transporter inhibition by Lasmiditan. Migraine [8A80] [21]
Rolapitant DM8XP26 Moderate Decreased clearance of Sitagliptin due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [22]
Enzalutamide DMGL19D Moderate Increased metabolism of Sitagliptin caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [23]
Fostamatinib DM6AUHV Moderate Decreased clearance of Sitagliptin due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [24]
⏷ Show the Full List of 10 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sodium stearyl fumarate E00545 23665634 lubricant
Calcium hydrogenphosphate E00294 24441 Diluent
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Magnesium stearate E00208 11177 lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Sitagliptin 50 mg tablet 50 mg Oral Tablet Oral
Sitagliptin 100 mg tablet 100 mg Oral Tablet Oral
Sitagliptin 25 mg tablet 25 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Sitagliptin FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6286).
3 ClinicalTrials.gov (NCT01619332) Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763. U.S. National Institutes of Health.
4 BDDCS applied to over 900 drugs
5 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6 Herman GA, Bergman A, Liu F, Stevens C, Wang AQ, Zeng W, Chen L, Snyder K, Hilliard D, Tanen M, Tanaka W, Meehan AG, Lasseter K, Dilzer S, Blum R, Wagner JA: Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol. 2006 Aug;46(8):876-86.
7 Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag. 2008;4(4):753-68.
8 Raemsch KD, Sommer J: Pharmacokinetics and metabolism of nifedipine. Hypertension. 1983 Jul-Aug;5(4 Pt 2):II18-24. doi: 10.1161/01.hyp.5.4_pt_2.ii18.
9 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
10 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
11 Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009 Oct;124(1):113-38.
12 265 effect of dietary cholesterol on gallbladder bile lithogenicity and gene expression in the enterohepatic axis of non-obese gallstone and control women. Journal of Hepatology, 2009, 50(09):S105-S106.
13 Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther. 2007 May;321(2):673-83.
14 Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
15 Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010 Aug;12(8):648-58.
16 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
17 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
18 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
19 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
20 Cerner Multum, Inc. "Australian Product Information.".
21 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
22 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
23 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
24 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.